Aspirin, warfarin and a thienopyridine for acute coronary syndromes

Yuval Konstantino1, Zaza Iakobishvili, Avital Porter

  • 1Department of Cardiology, Rabin Medical Center, Petah-Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Cardiology
|November 16, 2005
PubMed

Insights

Triple therapy (TT) using warfarin alongside dual therapy (DT) in acute coronary syndrome (ACS) patients is feasible. While TT patients experienced more bleeding events, adjusted mortality rates at 30 days and 6 months were similar between groups.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Dual therapy (DT) with clopidogrel and aspirin is standard for acute coronary syndrome (ACS).
  • Triple therapy (TT), involving warfarin in addition to DT, is sometimes necessary for specific ACS patient populations.

Purpose of the Study:

  • To investigate the incidence, complications, and outcomes associated with triple therapy (TT) in ACS patients.
  • To compare the safety and efficacy of TT versus DT in the management of ACS.

Main Methods:

  • Analysis of Israeli national surveys data for ACS patients from 2000 to 2004.
  • Comparison of patient demographics, treatment protocols, and clinical outcomes between TT and DT groups.

Main Results:

  • Triple therapy (TT) was administered to 1.3% of ACS patients (n=76), who were older and had more prior cardiac disease.
  • TT patients experienced higher rates of heart failure, arrhythmias, ischemia, and major bleeding (2.6% vs. 0.6%, p=0.03) during hospitalization.
  • No significant differences in adjusted 30-day and 6-month mortality were observed between the TT and DT groups.

Conclusions:

  • Triple therapy (TT) is a feasible treatment option for ACS patients requiring concurrent warfarin therapy.
  • Careful monitoring for complications, particularly bleeding, is essential in ACS patients undergoing TT.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...